These strategies aim to reduce TAM-mediated suppression, increase CD8+ T cell infiltration, and improve the efficacy of checkpoint inhibitors.Importantly, combination strategies—such as TREM2 blockade plus anti–PD-1/PD-L1 therapy—are being actively explored due to their synergistic effects in reversing T cell exclusion and enhancing tumor clearance (147–149). This evidence concerns the gene TREM2 and neoplasm.